Repare Therapeutics (RPTX) AI Stock Analysis

• Market Cap: $64.77M
• Dividend Yield: N/A
• Average Volume (3M): 505.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: -98.90%
• EPS Growth: -177.17%
• Country: US
• Employees: 129
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.71
• Shares Outstanding: 42,891,403
• 10 Day Avg. Volume: 203,526
• 30 Day Avg. Volume: 505,233
• PEG Ratio: 0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.58
• Enterprise Value/Market Cap: -0.24
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.22
• 1Y Price Target: $1.50
• Price Target Upside: -0.66% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 53 Neutral
• Price Target: $1.50 ▼(-0.66%Downside)

Repare Therapeutics' financial performance is the primary factor negatively impacting its score due to ongoing losses and revenue volatility. However, recent strategic corporate events and short-term technical indicators provide some positive outlook, balancing the overall score towards a moderate level.

Positive Factors

Financial Stability

Repare's cash runway extends into late-2027, providing financial stability and possibly further extended by the new agreement.

Pipeline Development

Pre-clinical data presented at AACR demonstrates RP-1664 efficacy in breast cancer models.

Strategic Partnerships

Repare announced entry into a worldwide, exclusive license agreement with Debiopharm around lunreserb, yielding $10M upfront and up to $257M in potential milestones.

Negative Factors

Financial Performance

Repare reported a Q1 net loss of $30MM.

Net Losses

Repare Therapeutics reported a net loss of $28.7 million for Q4 and $84.7 million for the fiscal year 2024.

Restructuring Challenges

The leadership transition comes in the wake of a previously-announced restructuring that includes a 75% workforce reduction and other leadership departures.

Repare Therapeutics Business Overview & Revenue Model

Company Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

How the Company Makes Money

Repare Therapeutics primarily generates revenue through strategic collaborations, research and development partnerships, and potential milestone payments related to the advancement of its drug candidates. The company partners with other pharmaceutical and biotechnology companies to co-develop and commercialize its proprietary therapies. Additionally, Repare Therapeutics could receive revenue from licensing agreements and, ultimately, from the commercialization of its approved drugs. The company's ability to advance its drug candidates through clinical trials and achieve regulatory approvals is critical to its revenue generation strategy.

Repare Therapeutics Financial Statement Overview

Summary

Repare Therapeutics is facing significant financial challenges with consistent losses and revenue volatility. However, the company's balance sheet shows relative stability with a strong cash position and low leverage. While the income and cash flow statements highlight operational inefficiencies, the company's liquidity offers some buffer to continue its operations and possibly improve in the future.

Income Statement

Repare Therapeutics has shown significant revenue volatility over the years, with revenue dropping to zero in the most recent period from $51.13 million the previous year and $131.83 million two years prior. The company has consistently incurred operating losses, and negative net income, indicating ongoing profitability challenges. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies. However, the company showed a brief revenue surge in 2022, which might indicate potential for recovery.

Balance Sheet

The company maintains a strong equity base relative to its liabilities, reflected in a low Debt-to-Equity ratio, which suggests stability. Despite consistent net losses, Repare's cash position remains robust, indicating prudent cash management. However, the Return on Equity is negative due to sustained net losses, which impacts overall shareholder returns negatively. The equity ratio has shown some decline but remains relatively healthy.

Cash Flow

Repare Therapeutics has faced challenges with negative free cash flow, although the cash flow from investing activities has been positive, largely due to asset management. The operating cash flow remains negative, indicating that the company is not generating enough cash from core operations to cover expenses. However, the company has managed to sustain cash reserves, which provides liquidity to continue operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	53.48M	51.13M	131.83M	7.60M	135.00K
Gross Profit	51.56M	-80.07M	127.65M	4.26M	-1.65M
EBITDA	-93.52M	-114.27M	-17.82M	-107.19M	-53.41M
Net Income	-84.69M	-93.80M	-29.05M	-106.91M	-53.42M
Balance Sheet
Total Assets	176.51M	253.90M	364.07M	368.71M	357.09M
Cash, Cash Equivalents and Short-Term Investments	152.79M	223.63M	343.94M	341.87M	333.71M
Total Debt	1.93M	3.41M	5.43M	7.31M	4.00M
Total Liabilities	25.38M	41.82M	84.56M	80.29M	70.26M
Stockholders Equity	151.13M	212.08M	279.52M	288.42M	286.83M
Cash Flow
Free Cash Flow	-76.44M	-129.10M	-280.00K	-87.49M	-8.32M
Operating Cash Flow	-76.44M	-127.16M	322.00K	-85.80M	-6.08M
Investing Cash Flow	49.47M	78.04M	-175.78M	-1.68M	-9.76M
Financing Cash Flow	542.00K	842.00K	880.00K	95.56M	247.84M

Repare Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPTX, the sentiment is Neutral. The current price of 1.51 is below the 20-day moving average (MA) of 1.52, above the 50-day MA of 1.45, and below the 200-day MA of 1.75, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 51.48 is Neutral, neither overbought nor oversold. The STOCH value of 13.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RPTX.

Repare Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	HK$17.40B	5.81	-7.44%	3.53%	11.55%	-28.15%
XLO	54 Neutral	$33.60M	―	-297.84%	―	―	53.92%
RPTX	53 Neutral	$64.77M	―	-71.64%	―	-98.90%	-177.17%
SPRO	48 Neutral	$129.71M	10.83	-107.28%	―	-71.68%	-397.61%
STTK	42 Neutral	$36.48M	―	-71.90%	―	69.65%	27.98%
OKUR	42 Neutral	$29.86M	―	-70.01%	―	―	71.57%
PRLD	35 Underperform	$44.03M	―	-81.44%	―	―	16.38%

Repare Therapeutics Corporate Events

Repare Therapeutics Signs Licensing Deal with Debiopharm

On July 15, 2025, Repare Therapeutics entered into an exclusive worldwide license agreement with Debiopharm International for the development and commercialization of lunresertib, a PKMYT1 inhibitor. The agreement grants Debiopharm rights to develop and market products containing lunresertib, either alone or in combination with Debio 0123. Repare will receive a $10 million upfront payment and potentially up to $257 million in milestone payments, along with royalties on global sales. This collaboration builds on their previous partnership and allows Debiopharm to assume responsibility for the ongoing MYTHIC clinical trial. The deal supports Repare’s focus on advancing its clinical priorities, particularly the ongoing Phase 1 trials for RP-3467 and RP-1664, with data expected in the latter half of 2025.

The most recent analyst rating on (RPTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics Updates Severance Benefits for Executives

On June 13, 2025, Repare Therapeutics Inc.’s Compensation Committee approved amendments to the severance benefits for certain officers, including Executive Vice President and Chief Scientific Officer Michael Zinda. These amendments provide Dr. Zinda with specific severance benefits if his employment is terminated without cause or if he resigns for good reason, not linked to a change in control. This decision reflects the company’s commitment to ensuring competitive compensation packages for its executives, potentially impacting its operational stability and stakeholder confidence.

The most recent analyst rating on (RPTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics Holds Annual Shareholder Meeting

On June 17, 2025, Repare Therapeutics held its Annual Meeting of Shareholders, where key decisions were made. Shareholders elected four directors to the board, approved executive compensation on a non-binding basis, and appointed Ernst & Young LLP as the independent registered public accounting firm for 2025.

The most recent analyst rating on (RPTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics Out-Licenses Platforms to DCx Biotherapeutics

On May 1, 2025, Repare Therapeutics announced an agreement to out-license its discovery platforms, including intellectual property, to DCx Biotherapeutics, a Canadian biotechnology company. This strategic move allows Repare to concentrate on its clinical portfolio and reduce costs while retaining an economic interest in the technologies. The agreement includes upfront payments of $4 million, a 9.99% equity stake in DCx, and potential future milestone payments and royalties. Additionally, DCx will acquire certain Repare assets, including laboratory facilities and personnel, enhancing its capabilities in developing precision drug conjugates.